Michael Bonelli News Today

Ann Brophy passed away in Danvers, This is the full obituary story where you can express condolences and share memories.

USA Lacrosse launched National Celebrate Lacrosse Week with clinics around the country.

Arrests by state and local police in the region.

Patients under immunosuppressive therapy, who do not respond to primary COVID-19 vaccination, have an increased risk for severe COVID-19 disease courses. Until now, it was not clear whether those patients at risk can benefit from an additional booster vaccination.

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows immunocompromised patients using rituximab (a drug used to treat diseases like rheumatoid arthritis) were able to produce antibodies against COVID-19 (seroconvert) after receiving a third COVID-19 vaccine dose, even if there was no development of the antibody after the first two doses of the vaccine.

ATLANTA — New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows immunocompromised patients

As Michael Bonelli, senior author of the Vienna study, explains: “B cells constitute an important cell population for the development of antibodies. We were able to show that more than 50% of patients receiving B-cell-depleting treatment with rituximab still develop antibodies to SARS-CoV-2 [Covid-19], and that there is potentially additional protection via a cellular immune response.” This underscores the importance of vaccinating immunosuppressed patients against Covid, Bonelli said, whil...